Related Experiment Video
Updated: Jul 3, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Recombinant factor VIIa for warfarin-associated intracranial bleeding
Can Ilyas1, Ginine M Beyer, Richard P Dutton
1Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Journal of Clinical Anesthesia
|July 12, 2008
Summary
Recombinant factor VIIa (rVIIa) effectively reverses warfarin-induced coagulopathy in trauma patients with intracranial hemorrhage (ICH). This treatment requires less plasma and offers faster INR correction compared to conventional methods.
Area of Science:
- Trauma care
- Hematology
- Pharmacology
Background:
- Warfarin is commonly used for anticoagulation but poses a bleeding risk, especially in trauma patients with intracranial hemorrhage (ICH).
- Reversing warfarin's effects in ICH patients is critical for managing coagulopathy and improving outcomes.
Purpose of the Study:
- To evaluate the efficacy of recombinant factor VIIa (rVIIa) in reversing warfarin-induced coagulopathy in trauma patients with ICH.
- To compare rVIIa treatment with conventional methods for INR correction in this patient population.
Main Methods:
- Retrospective, cohort-controlled database review at a Level 1 trauma center.
- Analysis of 54 patients with ICH on warfarin; 30 received rVIIa, 24 received conventional treatment.
- Outcomes assessed included coagulation studies (INR), blood product usage, time to reversal, duration of reversal, and mortality.
Main Results:
- Patients treated with rVIIa required significantly less plasma (4 vs. 7 units) for INR correction.
- INR correction was achieved in a shorter period with rVIIa (2.4 vs. 10 hours).
- The duration of corrected INR after rVIIa administration was dose-dependent.
Conclusions:
- Recombinant factor VIIa (rVIIa) offers prompt correction of INR in warfarin-treated patients with ICH.
- The duration of INR correction provided by rVIIa is dose-dependent.
- rVIIa represents an effective option for managing warfarin-induced coagulopathy in this critical patient group.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.